The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial

L. Dirven; M.J. van den Bent; A. Bottomley; N. van der Meer; B. van der Holt; M.J. Vos; A.M.E. Walenkamp; L.V. Beerepoot; M.C.J. Hanse; J.C. Reijneveld; A. Otten; F.Y.F.L. de Vos; M. Smits; J.E.C. Bromberg; W. Taal; M.J.B. Taphoorn

doi:10.1016/j.ejca.2015.03.025

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial

L. Dirven, M.J. van den Bent, A. Bottomley, N. van der Meer, B. van der Holt, M.J. Vos, A.M.E. Walenkamp, L.V. Beerepoot, M.C.J. Hanse, J.C. Reijneveld, A. Otten, F.Y.F.L. de Vos, M. Smits, J.E.C. Bromberg, W. Taal, M.J.B. Taphoorn

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1321-1330
Journal	European Journal of Cancer
Volume	51
Issue number	10
DOIs	https://doi.org/10.1016/j.ejca.2015.03.025
Publication status	Published - 2015

Access to Document

10.1016/j.ejca.2015.03.025

Cite this

Dirven, L., van den Bent, M. J., Bottomley, A., van der Meer, N., van der Holt, B., Vos, M. J., Walenkamp, A. M. E., Beerepoot, L. V., Hanse, M. C. J., Reijneveld, J. C., Otten, A., de Vos, F. Y. F. L., Smits, M., Bromberg, J. E. C., Taal, W., & Taphoorn, M. J. B. (2015). The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. European Journal of Cancer, 51(10), 1321-1330. https://doi.org/10.1016/j.ejca.2015.03.025

@article{6286a20ac56c44d981764d3f399e2c64,

title = "The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial",

author = "L. Dirven and {van den Bent}, M.J. and A. Bottomley and {van der Meer}, N. and {van der Holt}, B. and M.J. Vos and A.M.E. Walenkamp and L.V. Beerepoot and M.C.J. Hanse and J.C. Reijneveld and A. Otten and {de Vos}, F.Y.F.L. and M. Smits and J.E.C. Bromberg and W. Taal and M.J.B. Taphoorn",

year = "2015",

doi = "10.1016/j.ejca.2015.03.025",

language = "Undefined/Unknown",

volume = "51",

pages = "1321--1330",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

number = "10",

}

Dirven, L, van den Bent, MJ, Bottomley, A, van der Meer, N, van der Holt, B, Vos, MJ, Walenkamp, AME, Beerepoot, LV, Hanse, MCJ, Reijneveld, JC, Otten, A, de Vos, FYFL, Smits, M, Bromberg, JEC, Taal, W & Taphoorn, MJB 2015, 'The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial', European Journal of Cancer, vol. 51, no. 10, pp. 1321-1330. https://doi.org/10.1016/j.ejca.2015.03.025

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. / Dirven, L.; van den Bent, M.J.; Bottomley, A. et al.

In: European Journal of Cancer, Vol. 51, No. 10, 2015, p. 1321-1330.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial

AU - Dirven, L.

AU - van den Bent, M.J.

AU - Bottomley, A.

AU - van der Meer, N.

AU - van der Holt, B.

AU - Vos, M.J.

AU - Walenkamp, A.M.E.

AU - Beerepoot, L.V.

AU - Hanse, M.C.J.

AU - Reijneveld, J.C.

AU - Otten, A.

AU - de Vos, F.Y.F.L.

AU - Smits, M.

AU - Bromberg, J.E.C.

AU - Taal, W.

AU - Taphoorn, M.J.B.

PY - 2015

Y1 - 2015

U2 - 10.1016/j.ejca.2015.03.025

DO - 10.1016/j.ejca.2015.03.025

M3 - Article

C2 - 25899986

SN - 0959-8049

VL - 51

SP - 1321

EP - 1330

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 10

ER -